Video

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

Author(s):

Ursula Matulonis, M.D.
Conference|SGO Annual Meeting on Women's Cancer

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

PARP inhibitors work by blocking the repair of DNA within cancer cells, which then allows other DNA repair molecules to target the broken DNA strand.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Image of woman.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Related Content
INX-315 received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer: © stock.adobe.com.
April 29th 2025

FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer

Spencer Feldman
INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
From left: JILL REESE, M.S., APRN, AGCNS-BC, OCN, and SUSIE MALONEY, M.S., APRN, AOCN, AOCNS
April 27th 2025

Healer, Mentor and Leader

Susie Maloney, M.S., APRN, AOCN, AOCNS
Reflecting upon my relationship with Jill over the past 25 years, I am in awe of all she has accomplished.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
From left: KATHLEEN COUGHLIN, M.S.N., ANP-BC, BMTCN, and ANTONIA MALONEY, B.S.N., RN, OCN
April 24th 2025

The Fearless Patient Advocate

Antonia Maloney, BSN, RN, OSN
Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.”
MATTHEW MANGOLD, B.S.N., RN, and ERIN LONGSTRETH, M.S.N., RN, OCN, NEA-BC
April 22nd 2025

Advocacy and ‘Radiating Valor’ Have a Transformative Impact

Erin Longstreth, M.S.N., RN, OCN, NEA-BC